| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1051992805 |
| P356 | DOI | 10.1186/S12916-016-0705-4 |
| P932 | PMC publication ID | 5078889 |
| P698 | PubMed publication ID | 27776519 |
| P50 | author | Junna Oba | Q41599738 |
| Francesco C. Stingo | Q42584915 | ||
| Jason Roszik | Q43024914 | ||
| Jeffrey E Gershenwald | Q56955611 | ||
| P. Andrew Futreal | Q63232438 | ||
| Cara Haymaker | Q63452882 | ||
| Funda Meric-Bernstam | Q67191264 | ||
| Michael T Tetzlaff | Q88105633 | ||
| Michael A Davies | Q88387606 | ||
| Kenneth Hess | Q89297362 | ||
| Patrick Hwu | Q89392895 | ||
| Tatiana Karpinets | Q89811947 | ||
| Chantale Bernatchez | Q90161715 | ||
| Don L Gibbons | Q92340218 | ||
| Lauren E Haydu | Q104485018 | ||
| Kenna Mills Shaw | Q114384218 | ||
| Scott E Woodman | Q114577601 | ||
| Gordon B. Mills | Q28086262 | ||
| Jennifer Wargo | Q32650026 | ||
| Alexander J. Lazar | Q37838894 | ||
| P2093 | author name string | Ken Chen | |
| Veera Baladandayuthapani | |||
| Marie-Andrée Forget | |||
| Agda K Eterovic | |||
| Alan E Siroy | |||
| Aron Y Joon | |||
| Jie Qing Chen | |||
| Laszlo G Radvanyi | |||
| P2860 | cites work | Advances in the development of cancer immunotherapies | Q38049010 |
| High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma | Q38926293 | ||
| Clinical actionability enhanced through deep targeted sequencing of solid tumors | Q41519437 | ||
| Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy | Q41983246 | ||
| A landscape of driver mutations in melanoma | Q24603357 | ||
| Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma | Q24607661 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Comprehensive molecular profiling of lung adenocarcinoma | Q28244995 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing | Q28275103 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Final version of 2009 AJCC melanoma staging and classification | Q29614803 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 | ||
| Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors | Q33606161 | ||
| Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer | Q33862861 | ||
| High sensitivity of cancer exome-based CD8 T cell neo-antigen identification | Q33930588 | ||
| New strategies in melanoma: molecular testing in advanced disease | Q33943660 | ||
| Genomic Classification of Cutaneous Melanoma | Q34670776 | ||
| A scaling aneurysm model-based approach to assessing the role of flow pattern and energy loss in aneurysm rupture prediction. | Q36082006 | ||
| Molecular and genetic properties of tumors associated with local immune cytolytic activity | Q36869059 | ||
| Genomic correlates of response to CTLA-4 blockade in metastatic melanoma | Q37319470 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 168 | |
| P577 | publication date | 2016-10-25 | |
| P1433 | published in | BMC Medicine | Q4835947 |
| P1476 | title | Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. | |
| P478 | volume | 14 |
| Q102389007 | A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy |
| Q92796464 | Application of PD-1 Blockade in Cancer Immunotherapy |
| Q92666578 | Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay |
| Q47104481 | BRAF inhibitors: resistance and the promise of combination treatments for melanoma |
| Q52385841 | Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic |
| Q33806351 | Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators |
| Q93012736 | Circulating biomarkers predictive of tumor response to cancer immunotherapy |
| Q47625086 | Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. |
| Q47617121 | Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. |
| Q41475564 | Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy |
| Q50058145 | Emerging biomarkers for cancer immunotherapy in melanoma. |
| Q92934400 | Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy |
| Q92315030 | Immunotherapy and next-generation sequencing guided therapy for precision oncology: What have we learnt and what does the future hold? |
| Q64229216 | Implementing TMB measurement in clinical practice: considerations on assay requirements |
| Q59798115 | Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians |
| Q64098332 | In silico learning of tumor evolution through mutational time series |
| Q39329609 | Interaction of molecular alterations with immune response in melanoma. |
| Q64886119 | Liquid biopsies for hepatocellular carcinoma. |
| Q54115719 | Melanoma: What do all the mutations mean? |
| Q89221773 | Mining Public Databases for Precision Oncology |
| Q61810151 | Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update |
| Q55261882 | Mutation load estimation model as a predictor of the response to cancer immunotherapy. |
| Q64091350 | PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions |
| Q47120629 | PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? |
| Q100737103 | Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients |
| Q64914214 | Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. |
| Q47101836 | Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM). |
| Q39130451 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy |
| Q53081522 | Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. |
| Q90353808 | Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC |
| Q47862144 | Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls. |
| Q39078341 | T cell exhaustion: from pathophysiological basics to tumor immunotherapy |
| Q89450228 | Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment |
| Q92092437 | The role of the immune system in brain metastasis |
| Q89934254 | Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens |
| Q98466949 | Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types |
| Q62745707 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types |
Search more.